RITUXIMAB
Clinical Indication
IgM paraproteinaemic demyelinating peripheral neuropathy in adults
Comments
Approved centres only. LLR is currently not an approved centre.
Date of classification
February 2022
Do not prescribe
Drugs not recommended for use in LLR because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety.